Anastomotic Leak in Ovarian Cancer Cytoreduction Surgery: A Systematic Review and Meta-Analysis
Authors:
- Massimiliano FornasieroMFMassimiliano Fornasiero
- Georgios GeropoulosGGGeorgios Geropoulos
- Konstantinos S. KechagiasKonstantinos S. Kechagias
- Kyriakos PsarrasKPKyriakos Psarras
- Konstantinos Katsikas TriantafyllidisKTKonstantinos Katsikas Triantafyllidis
- Panagiotis GiannosPGPanagiotis Giannos
- Georgios KoimtzisGKGeorgios Koimtzis
- Nikoletta A. PetrouNPNikoletta A. Petrou
- James LucocqJLJames Lucocq
- Christos KontovounisiosCKChristos Kontovounisios
- Dimitrios GiannisDGDimitrios Giannis
Open Access
Abstract
Introduction: Anastomotic leaks (AL) following ovarian cytoreduction surgery could be detrimental, leading to significant delays in commencing adjuvant chemotherapy, prolonged hospital stays and increased morbidity. The aim of this study was to investigate risk factors associated with anastomotic leaks after ovarian cytoreduction surgery. Material and methods: The MEDLINE (via PubMed), Cochrane Library, EMBASE and Scopus bibliographical databases were searched. Original clinical studies investigating risk factors for AL in ovarian cytoreduction surgery were included. Results: Eighteen studies with non-overlapping populations reporting on patients undergoing cytoreduction surgery for ovarian cancer (n = 4622, including 344 cases complicated by AL) were included in our analysis. Patients undergoing ovarian cytoreduction surgery complicated by AL had a significantly higher rate of 30-day mortality but no difference in 60-day mortality. Multiple bowel resections were associated with an increased risk of postoperative AL, while no association was observed with body mass index (BMI), American Society of Anesthesiologists (ASA) score, age, smoking, operative approach (primary versus interval cytoreductive, stapled versus hand-sewn anastomoses and formation of diverting stoma), neoadjuvant chemotherapy and use of hyperthermic intraperitoneal chemotherapy (HIPEC). Discussion: Multiple bowel resections were the only clinical risk factor associated with increased risk for AL after bowel surgery in the ovarian cancer population. The increased 30-day mortality rate in patients undergoing ovarian cytoreduction complicated by AL highlights the need to minimize the number of bowel resections in this population. Further studies are required to clarify any association between neoadjuvant chemotherapy and decreased AL rates.Keywords
This publication has 54 references indexed in Scilit:
- Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomesGynecologic Oncology, 2012
- Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian CancerInternational Journal of Gynecological Cancer, 2011
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Risk Factors for Anastomotic Leakage after Laparoscopic Rectal ResectionJournal of the Korean Society of Coloproctology, 2010
- Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer - a prospective multicenter phase II trial (PRIMOVAR)Oncology Reports, 2009
- Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal CarcinomatosisAnnals of Surgical Oncology, 2009
- Systematic Review and Meta-Analysis of the Role of Defunctioning Stoma in Low Rectal Cancer SurgeryAnnals of Surgery, 2008
- The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concernsGynecologic Oncology, 2006
- Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancerGynecologic Oncology, 2006
- Early infective complications and late recurrent cancer in stapled colonic anastomosesDiseases of the Colon & Rectum, 1989